Highlights
- •Remdesivir is the only antiviral approved for COVID-19.
- •Remdesivir treatment was associated with transient bradycardia.
- •Bradycardia did not cause any severe clinical manifestation.
As described recently in this journal, natural coronavirus diseases 2019 (COVID-19) is associated with cardiac arrhythmias
[1]
; cardiovascular complications were risk factors for severe COVID-19 and poor outcome[1]
as well as increased CD4/CD8 ratio, fever, LDH >250 U/l, d-dimer >1000 ng/ml.[2]
,- Suardi L.R.
- Pallotto C.
- Esperti S.
- Tazzioli E.
- Baragli F.
- Salomoni E.
- et al.
Risk factors for non-invasive/invasive-ventilatory support in patients with COVID-19 pneumonia: a retrospective study within a multidisciplinary approach.
Int J Infect Dis. 2020; (S1201-9712(20)30728-1(online ahead of print))https://doi.org/10.1016/j.ijid.2020.09.012
[3]
Remdesivir, a viral RNA-dependent RNA-polymerase inhibitor, was authorized for severe COVID-19 patients without mechanical ventilation
[4]
but still little is known about its safety except for reports about hepatic disorders and skin reactions.[5]
More recently, concern arose about RDV-related cardiac adverse events, especially bradycardia.[6]
–[9]
The purpose of this study is to describe bradycardia incidence in a group of directly-observed COVID-19 patients and its possible association with RDV.- Touafchia A.
- Bagheri H.
- Carrié D.
- Durrieu G.
- Sommet A.
- Chouchana L.
- et al.
Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns.
Clin Microbiol Infect. 2021; (S1198-743X(21)00094[online ahead of print])https://doi.org/10.1016/j.cmi.2021.02.013
We retrospectively evaluated all the patients consecutively admitted to our ward with COVID-19 confirmed diagnosis from September 14th to December 14th 2020. We excluded ( i) patients coming from other wards and/or hospitals, (ii) patients that did not receive a complete course of RDV during their stay in our ward, (iii) patients with life expectancy <48 h at admission. The study population was divided into 2 groups: patients who received RDV (cases) and patients who did not receive RDV (controls).
We collected data about demographic and clinical characteristics, laboratory tests, treatments and outcome using an electronic case report form. Heart rate (HR) was measured at least 3 to 6 times daily according to patients’ clinical conditions. RDV was administered as follows: 200 mg as loading dose on Day 1 and 100 mg on Day 2 to 5.
Transient bradycardia was defined as HR <60 bpm in two consecutive measurements or HR <50 bpm in one measurement. To be considered "positive for bradycardia”, cases had not presented other bradycardia episodes before or after RDV administration period. Positive outcome was defined as clinical healing and/or discharge independently of the virological status.
We compared bradycardia incidence between cases and controls and we evaluated risk factors for bradycardia by univariate and multivariate logistic regression. Moreover, as a post hoc analysis, we performed a univariate and multivariate logistic regression analysis about risk factors for mortality.
Frequencies and medians were compared using chi-squared test and Mann–Whitney U test, respectively. Statistical analysis was made using SPSS vers. 23.
We enrolled 141 patients, 62 cases and 79 controls. Table 1 shows patients’ characteristics at admission, treatments and outcomes. Cases and controls are homogeneous at admission except for body temperature >38 °C. Transient bradycardia was observed in 29/62 (46.8%) cases and 22/79 (27.8%) controls (p = 0.023). Univariate and multivariate logistic regression analysis confirmed the association between RDV treatment and bradycardia (OR 2.153, 95%CI 1.052–4.405, p = 0.036) (Table 2). All patients were asymptomatic for bradycardia, and we did not observe any cardiac event nor electrocardiographic clinically significant alterations in both groups.
Table 1Cases’ and controls’ characteristics at admission, treatments and outcomes.
| Study population n = 141 | Cases n = 62 | Controls n = 79 | P | |
|---|---|---|---|---|
| Female sex n (%) | 66 (46.8) | 32 (51.6) | 34 (43) | >0.1 |
| Age years, median (IQR) | 69 (56–80) | 69 (59–80.75) | 67 (53.5–80) | >0.1 |
| CCI median (IQR) | 4 (1–5) | 4 (2–5) | 3 (1–6) | >0.1 |
| CVD n (%) | 84 (59.6) | 40 (64.5) | 44 (55.7) | >0.1 |
| Beta-blockers n (%) | 46 (32.6) | 19 (30.6) | 27 (34.2) | >0.1 |
| Days onset-admissionmedian (IQR) | 6 (4–7) | 6 (4.25–7) | 7 (3–8.5) | >0.1 |
| T ≥ 38°C n (%) | 23 (16.3) | 16 (25.8) | 7 (8.9) | 0.011 |
| PaO2/FiO2 <300 n (%) | 60 (42.6) | 31 (50) | 29 (36.7) | >0.1 |
| C-RP >5 mg/dl n (%) | 94 (66.7) | 46 (74.2) | 48 (60.8) | >0.1 |
| C-RP mg/dl median (IQR) | 7.8 (3–12.36) | 8.93 (5.01–12.92) | 6.76 (2.3–11.17) | 0.077 |
| Lymphocytes <800/mm3 n (%) | 56 (39.7) | 26 (41.9) | 30 (38) | >0.1 |
| Lymphocytes n/mm3 median (IQR) | 920 (650–1310) | 890 (595–1185) | 970 (700–1340) | >0.1 |
| IL-6a pg/ml median (IQR) | 29.9 (9.05–78.75) | 30.25 (13.4–51.025) | 28.8 (7.6–86.725) | >0.1 |
| d-dimer >1000 ng/ml n (%) | 59 (41.8) | 21 (33.9) | 38 (48.1) | >0.1 |
| d-dimer ng/ml median (IQR) | 789 (473–1399.5) | 720.5 (480–1155) | 964 (472–1595) | >0.1 |
| CD4/CD8a median (IQR) | 1.9 (1.2–2.65) | 2.1 (1.3–3.1) | 1.6 (0.975–2.3) | 0.069 |
| Bradycardia n (%) | 51 (36.2) | 29 (46.8) | 22 (27.8) | 0.023 |
| Steroids n (%) | 129 (91.5) | 62 (100) | 67 (84.8) | >0.1 |
| LMWH n (%) | 139 (98.6) | 62 (100) | 77 (97.5) | >0.1 |
| Exitus n (%) | 24 (17) | 6 (9.7) | 18 (22.8) | 0.045 |
Abbreviations: CCI, Charlson comorbidity index; CVD, cardiovascular diseases; Days onset-admis, days from disease onset to hospital admission; T, temperature; C-RP, C-reactive protein; IL-6, interleukin 6; LMWH, low molecular weight heparin.
Notes: a, n = 83, 49 patients and 34 controls.
Table 2Univariate analysis and multivariate logistic regression assessing risk factors for transient bradycardia and for mortality.
| Transient Bradycardia | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) | p | |
| Female sex | 1.62 (0.807–3.256) | 0.175 | ||
| Age | 1.025 (1.000–1.051) | 0.048 | 1.016 (0.986–1.047) | 0.291 |
| CVD | 2.1 (1.011–4.362) | 0.047 | 1.628 (0.643–4.125) | 0.304 |
| Beta-blockers | 1.385 (0.671–2.86) | 0.378 | 0.935 (0.389–2.244) | 0.88 |
| T ≥38°C | 1.075 (0.421–2.742) | 0.88 | ||
| Lymphocytes | 1 (0.999–1) | 0.402 | ||
| C-RP | 1.027 (0.982–1.074) | 0.246 | ||
| d-dimer | 1 (1-1) | 0.934 | ||
| RDV therapy | 2.277 (1.13–4.588) | 0.021 | 2.153 (1.052–4.405) | 0.036 |
| PaO2/FiO2 <300 | 1.161 (0.577–2.337) | 0.676 | ||
| Mortality | ||||
| Female sex | 0.405 (0.156–1.049) | 0.063 | 0.267 (0.072–0.997) | 0.049 |
| Age | 1.138 (1.072–1.208) | <0.001 | 1.138 (1.046–1.238) | 0.003 |
| CCI | 1.63 (1.281–2.074) | <0.001 | 0.977 (0.636–1.499) | 0.914 |
| Days onset-admission | 0.799 (0.679–0.94) | 0.007 | 0.759 (0.603–0.956) | 0.019 |
| PaO2/FiO2 <300 | 1.523 (0.62–3.738) | 0.359 | ||
| Pneumonia | 1.029 (0.273–3.875) | 0.966 | ||
| T ≥38°C | 1.447 (0.479–4.373) | 0.655 | ||
| Lymphocytes | 0.999 (0.998–1) | 0.256 | ||
| C-RP | 1.082 (1.024–1.143) | 0.005 | 1.11 (1.022–1.206) | 0.013 |
| IL-6a | 1 (0.999–1.002) | 0.58 | ||
| d-dimer | 1.0001 (1–1.0003) | 0.055 | 1 (1-1) | 0.78 |
| CD4/CD8 | 0.62 (0.326–1.179) | 0.145 | ||
| LMWH administration | 0.198 (0.012–3.286) | 0.259 | ||
| Steroids administration | 5.806 (0.332–101.45) | 0.228 | ||
Abbreviations: OR, odds ratio; CI, confidential interval; CVD, cardiovascular diseases, T, body temperature; C-RP, C-reactive protein; RDV, remdesivir; CCI, Charlson comorbidity index; IL-6, interleukin 6; LMWH, low molecular weight heparin.
Mortality was higher in the control group (22.8% vs 9.7%, p = 0.045). To better understand this finding, we performed a univariate and multivariate logistic regression for the assessment of risk factors for mortality. Although RDV still represented a protective factor at the univariate analysis, this finding was not confirmed at the multivariate model (OR 0.3, 95%CI 0.086–1.049, p = 0.059) (Table 2). Age and elevated C-RP, instead, were risk factors for mortality, while female sex and a longer time from disease's onset to admission as protective ones (OR 0.827, 95%CI 0.701–0.976, p = 0.025). In particular, patients with negative outcome were admitted to the hospital after a median of 4 days (interquartile range [IQR] 2–6.25 days) from the onset of the symptoms, while patients with a positive outcome after 6 days (IQR 4–8 days) with p = 0.047.
Our study described transient bradycardia as a very common finding in patients administered with RDV (incidence about 47%). With this study, we confirmed the previously published data by our group, in which 60% of patients treated with RDV had transient bradycardia.
[8]
Some other authors also described this association in case reports and small reviews.[6]
,[7]
How RDV could provoke bradycardia is still unknown. A possible explanation comes from the similarity between a nucleotide triphosphate metabolite of RDV and adenosine triphosphate (ATP).[10]
ATP has a negative chronotropic and dromotropic activity by an adenosine-mediated pathway; this mechanism was hypothesised to be also used by RDV's metabolite.[9]
,- Touafchia A.
- Bagheri H.
- Carrié D.
- Durrieu G.
- Sommet A.
- Chouchana L.
- et al.
Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns.
Clin Microbiol Infect. 2021; (S1198-743X(21)00094[online ahead of print])https://doi.org/10.1016/j.cmi.2021.02.013
[10]
We found an elevated incidence of bradycardia. On the other hand, Touafchia and colleagues in a recently published extensive article reported only 94 cases of bradycardia out of 2603 RDV side effects reports.
[9]
Moreover, we did not observe any severe adverse event while in the above-mentioned study, 80% were serious, and 17% were fatal.- Touafchia A.
- Bagheri H.
- Carrié D.
- Durrieu G.
- Sommet A.
- Chouchana L.
- et al.
Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns.
Clin Microbiol Infect. 2021; (S1198-743X(21)00094[online ahead of print])https://doi.org/10.1016/j.cmi.2021.02.013
[9]
These substantial differences may lie in the design of the studies. While we directly observed every enrolled patient, Touafchia and colleagues evaluated “just” a big amount of reports of possible RDV associated adverse events. Theoretically, the indirect observation might be considered as a sort of selection bias that could lead to underestimating the incidence of bradycardia. At the same time, the small sample size of our study was probably responsible for the lack of severe adverse events.- Touafchia A.
- Bagheri H.
- Carrié D.
- Durrieu G.
- Sommet A.
- Chouchana L.
- et al.
Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns.
Clin Microbiol Infect. 2021; (S1198-743X(21)00094[online ahead of print])https://doi.org/10.1016/j.cmi.2021.02.013
In the first analysis, we found RDV administration significantly associated with positive outcome. This finding made mandatory an additional post hoc analysis that did not confirmed RDV association with reduced mortality, while the threshold of significance was reached by other factors such as C-RP, age, female sex. These data were consistent with the literature.
[4]
Since patients receiving RDV had a greater clinical improvement and a faster time to recovery, they did not have benefits in terms of mortality.[4]
This study had some limitations, especially the limited sample size and the retrospective design. However, it was performed in a real-life setting and provided directly-observed data that could possibly improve the clinical management of COVID-19 patients.
In conclusion, RDV is associated with a quite high incidence of transient bradycardia. Clinicians should be aware of this frequent adverse event in order to provide appropriate care to COVID-19 patients. A serial electrocardiographic control during RDV administration could be suggested to avoid severe cardiologic adverse events.
Ethics
Patients provided their consent for data analysis and submission
Authors’ contribution
CP, AG, LM, PB and MADP conceived the study; CP, LRS, SE, FV, ADE, PP, LA, ES and FB collected data; CP drafted the manuscript; CP, LRS, AG, LM, PB, DF, SE, FV, ADE, PP, LA, ES and FB revised the manuscript; CP, PB, DF and MADP supervised the study. All Authors approved the final version of the manuscript to be submitted.
Acknowledgments
CP received funds for speaking at symposia organised on behalf of Merck, Angelini, Zambon and Bristol Myers Squibb.
References
- Clinical characteristics of COVID-19 patients with complication of cardiac arrhythmia.J Infect. 2020; 81: e6-e8
- Risk factors for non-invasive/invasive-ventilatory support in patients with COVID-19 pneumonia: a retrospective study within a multidisciplinary approach.Int J Infect Dis. 2020; (S1201-9712(20)30728-1(online ahead of print))https://doi.org/10.1016/j.ijid.2020.09.012
- Increased CD4/CD8 ratio as a risk factor for critical illness in coronavirus disease 2019 (COVID-19): a retrospective multicentre study.Infect Dis. 2020; 52 (Lond): 675-677
- Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19.Infect Dis Soc Am. 2021; (version 4.1.0. Available at . Accessed March 15th 2021)
- Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19.Eur J Clin Pharmacol. 2021; 77: 435-437
- Sinus bradycardia associated with remdesivir treatment in COVID-19: a case report and literature review.J Cardiovasc Dev Dis. 2021; 8: 18
- Marked sinus bradycardia associated with remdesivir in COVID-19: a case and literature review.JACC Case Rep. 2020; 2: 2260-2264
- Potential remdesivir-related transient bradycardia in patients with coronavirus disease 2019 (COVID-19).J Med Virol. 2021; 93: 2631-2634
- Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns.Clin Microbiol Infect. 2021; (S1198-743X(21)00094[online ahead of print])https://doi.org/10.1016/j.cmi.2021.02.013
- Remdesivir is a direct antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.J Biol Chem. 2020; 295: 2835-2836
Article info
Publication history
Published online: May 27, 2021
Accepted:
May 23,
2021
Received:
May 17,
2021
Identification
Copyright
© 2021 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
